On July 16, 2012, the US Food and Drug Administration (FDA) approved a daily oral antiretroviral drug to reduce the risk of sexual acquisition of human immunodeficiency virus (HIV) infection by uninfected adults.1,2 Emtricitabine/tenofovir disoproxil fumarate (marketed by Gilead as Truvada) contains 2 nucleoside analogue HIV-1 reverse transcriptase inhibitors. Initially approved in 2004 to treat HIV infection in combination with other antiretroviral medications in people 12 years of age and older, emtricitabine/tenofovir costs about $13 900 a year in the United States for a year of treatment.
Steinbrook R. Preexposure Prophylaxis for HIV Infection. JAMA. 2012;308(9):865–866. doi:10.1001/jama.2012.9885
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: